Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 3, 1999, Pages 984-992

  Löscher, Wolfgang ^a   Lehmann, Holger ^a,c   Teschendorf, Hans Jürgen ^b   Traut, Martin ^b   Gross, Gerhard ^b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b Knoll AG   (Germany)

^c BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIMETHYL 7 (2 ISOPROPYL 1,3,4 THIADIAZOL 5 YL)METHOXYCOUMARIN; AMINE OXIDASE (FLAVIN CONTAINING); ESUPRONE; MONOAMINE OXIDASE INHIBITOR; SELEGILINE; TRANYLCYPROMINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; DRUG EFFECT; DRUG TOLERANCE; EPILEPSY; FEMALE; KINDLING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTICONVULSANTS; BRAIN; COUMARINS; ELECTRIC STIMULATION; EPILEPSY, TEMPORAL LOBE; FEMALE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RATS; RATS, WISTAR; SELEGILINE; TRANYLCYPROMINE;

EID: 0037549872     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Celada P and Artigas F (1993) Plasma 5-hydroxyindoleacetic acid as an indicator of monoamine oxidase-A inhibition in rat brain and peripheral tissues. J Neurochem 61:2191-2198.
2. Corcoran ME and Weiss GK (1990) Noradrenaline and kindling revisited, in Kindling (Wada JA ed) vol 4, pp 141-156, Plenum Press, New York.
3. Da Prada M, Kettler R, Keller HH, Cesura AM, Richards JG and Marti JS (1990) From moclobemide to Ro 19-6327 and Ro 41-1049: The development of a new class of reversible, selective MAO-A and MAO-B inhibitors. J Neural Transm 29(Suppl):279-292.
4. Dostert P, Strolin-Benedetti M and Tipton KF (1991) New anticonvulsants with selective MAO-B inhibitory activity. Eur J Neuropsychopharmacol 1:317-319.
5. Drescher K, Fischer von Weikersthal S, Weifenbach H and Traut M (1993) Characterization of the selective and reversible monoamine oxidase B inhibitor LU 53439 in vitro and in vivo. Naunyn-Schmiedeberg's Arch Pharmacol 347(Suppl):R135.
6. Ebert U, Cramer S and Löscher W (1997) Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn-Schmiedeberg's Arch Pharmacol 356:341-347.
7. Freeman FG and Jarvis MF (1981) The effect of interstimulation interval on the assessment and stability of kindled seizure threshold. Brain Res Bull 7:629-633.
8. Gerlach M, Riederer P and Youdim MBH (1992) The molecular pharmacology of 1.-deprenyl. Eur J Pharmacol-Molec Pharm 226:97-108.
9. Gerlach M, Youdim MBH and Riederer P (1996) Pharmacology of selegiline. Neurology 47:S137-S145.
10. Glover V and Sandler M (1986) Clinical chemistry of monoamine oxidase. Cell Biochem Funct 4:89-97.
11. Hönack D and Löscher W (1995) Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36:763-771.
12. Kilian M and Frey H-H (1973) Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 12:681-692.
13. Knoll J (1978) On the dual nature of monoamine oxidase. Horiz Biochem Biophys 5:37.
14. Knoll J (1986) The pharmacology of (-)deprenyl. J Neural Transm 22(Suppl):75-89.
15. Knoll J (1992) The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans - A personal view. Pharmacol Toxicol 70:317-321.
16. Knoll J (1998) (-)Deprenyl (Selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol Toxicol 82:57-66.
17. Lange KW, Riederer P and Youdim MBH (1994) Biochemical actions of 1-deprenyl (selegiline). Clin Pharmacol Ther 56:734-741.
18. Löscher W and Hönack D (1992) The behavioural effects of MK-801 in rats: Involvement of dopaminergic, serotonergic and noradrenergic systems. Eur J Pharmacol 215:199-208.
19. Löscher W and Hönack D (1995) Anticonvulsant and antiepileptogenic effect of 1.-deprenyl (selegiline) in the kindling model of epilepsy. J Pharmacol Exp Ther 274:307-314.
20. Löscher W and Lehmann H (1996) 1.-Deprenyl (selegiline) exerts anticonvulsant effects against different seizure types in mice. J Pharmacol Exp Ther 277:1410-1417.
21. Löscher W and Lehmann H (1998) Anticonvulsant efficacy of 1.-deprenyl (Selegiline) during chrionic treatment in mice: Continuous versus discontinuous administration. Neuropharmacology 37:1587-1593.
22. Löscher W and Schmidt D (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2:145-181.
23. Löscher W and Schmidt D (1994) Strategies in antiepileptic drug development: Is rational drug design superior to random screening and structural variation? Epilepsy Res 17:95-134.
24. Magyar K (1993) Pharmacology of monoamine oxidase B inhibitors, in Inhibitors of Monoamine Oxidase B. Pharmacology and Clinical Use in Neurodegenerative Disorders (Szelenyi I ed) pp 125-144, Birkhäuser, Basel.
25. Magyar K and Töthfalusi L (1984) Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm 36:373-384.
26. Medvedev A, Gorkin V, Shvedov V, Fedotova O, Fedotova I and Semiokhina A (1992) Efficacy of pirlindole, a highly selective reversible inhibitor of monoamine oxidase type A, in the prevention of experimentally induced epileptic seizures. Drug Invest 4:501-507.
27. Mukhopadhyay M, Upadhyay SN and Battacharya SK (1987) Neuropharmacological studies on selective monoamine oxidase A and B inhibitors. Indian J Exp Biol 25:761-770.
28. Murphy DL, Mitchell PB and Potter WZ (1995) Novel pharmacological approaches to the treatment of depression, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds), pp 1143-1153, Raven Press, New York.
29. Olanow CW (1996) Deprenyl in the treatment of Parkinson's disease: Clinical effects and speculations on mechanism of action. J Neural Transm (Suppl):75-84.
30. Palomo T, Beninger R and Archer T (1996) Neurotoxicity and functional concomitants in neurodegenerative brain disorders, in Dopamine Disease States (Beninger RJ, Palomo T and Archer T eds) pp 569-605, Editorial CYM, Madrid.
31. Peterson SL and Albertson TE (1982) Neurotransmitter and neuromodulator function in the kindled seizure and state. Progr Neurobiol 19:237-270.
32. Przegalinski E (1985) Monoamines and the pathophysiology of seizure disorders, in Antiepileptic Drugs (Frey H-H and Janz D eds), pp 101-137, Springer Verlag, Berlin.
33. Racine RJ (1972) Modification of seizure activity by electrical stimulation: II. Motor seizure. Electroencephalogr Clin Neurophysiol 32:281-294.
34. Robinson JB, Bocchinfuso R and Khalil A (1995) Irreversible inhibition of rat liver mitochondrial MAO A and MAO B by enantiomers of deprenyl and α-methylpargyline. J Pharm Pharmacol 47:324-328.
35. Rundfeldt C, Hönack D and Löscher W (1990) Phenytoin potently increases the threshold for focal seizures in amygdala-kindled rats. Neuropharmacology 29:845-851.
36. Sato M, Racine RJ and McIntyre DC (1990) Kindling: Basic mechanisms and clinical validity. Electroencephalogr Clin Neurophysiol 76:459-472.
37. Sparks DL and Buckholtz NS (1985) Combined inhibition of serotonin uptake and oxidative deamination attenuates audiogenic seizures in DBA/2J mice. Pharmacol Biochem Behav 23:753-757.
38. Strolin-Benedetti M, Marrari P, Colombo M, Castelli MG, Arand M, Oesch F and Dostert P (1994) The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 46: 814-819.
39. Tatton WG and Chalmersredman RME (1996) Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171-S183.
40. Tatton WG, Wadia JS, Ju WYH, Chalmersredman RME and Tatton NA (1996) (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl 48:45-59.
41. Traut M, Weifenbach H, Teschendorf H-J and Hofmann HP (1992) Biochemical and pharmacological characterization of esuprone, a new selective and reversible inhibitor of monoamine oxidase A. Naunyn-Schmiedeberg's Arch Pharmacol 345(Suppl):R124.
42. Ulugol A, Karadag HC, Dokmeci D, Al-Khatib I and Dokmeci I (1995) The protective effect of moclobemide against hypoxia-induced lethality in mice is not due to a decrease in body temperature. Pharmacol Biochem Behav 51:245-247.
43. Wahnschaffe U and Löscher W (1992) Lack of changes in seizure susceptibility during the estrous cycle in kindled rats. Epilepsy Res 13:199-204.
44. Yu PH (1994) Pharmacological and clinical implications of MAO-B inhibitors. Gen Pharmacol 25:1527-1539.